Connect with us

Hi, what are you looking for?

Monday, Dec 5, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Business

Tilray launches new medical products and training program in Australia

The company says it’s using learnings from operations in Germany to better meet patient needs

Tilray launches new medical products and training program in Australia
Image by Fir0002/Flagstaffotos via Wikimedia Commons

After reporting several quarters of disappointing domestic sales, Canadian mega-producer Tilray Brands, Inc. (TSX: TLRY) (Nasdaq: Tilray) is expanding its presence in key international markets like Australia.

In a statement Tuesday, the company said 15-gram offerings of its branded, GMP-certified cannabis flower is available to Aussie patients.

In the same breath, Tilray revealed the launch of its medical pot education platform for healthcare professionals in Australia and New Zealand.

The firm says the new product offering is approved under the Therapeutic Goods Administration’s special access to authorized prescriber scheme. The products include one-to-one balanced flower, mid-range and high-THC varieties.

After listening to patient feedback and other learnings from Tilray operations in Germany, the offerings in Australia will meet consumer needs there, says Denise Faltischek, chief strategy officer.

“As medical cannabis demand increases worldwide, we remain committed to providing healthcare professionals and patients with safe and reliable access to the highest-quality medical cannabis products.”

Read more: Tilray ekes out Q2 profit despite 16% drop in pot sales

Read more: Luxembourg short on medical pot after ‘supply problems’ with Tilray

According to George Plimenakos, Tilray’s general manager in Australia and New Zealand, “Cannabis education is paramount to everything we do and are therefore excited to offer healthcare professionals with the tools they need to learn about cannabis through our new e-learning platform.”

The company’s new education platform is designed to help healthcare professionals understand the benefits of medical cannabis. Previously, Tilray says it’s been educating practitioners at workshops, training “hundreds” in 2021.

The firm also partners with several research institutions including the Murdoch Children’s Research Institute in Australia, which is using Tilray’s products in experimental pediatric treatments for patients with “intellectual” conditions and severe behavioural problems; the government of New South Wales and the University of Sydney to develop treatments for chemotherapy-induced nausea; and another study with the university examining the effects of driving under the influence of pot.

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Business

The company will sell its cultivars Khiron Gelato 19/1 and Khiron Caramel 5/7 in the mountainous region

CBD

Previously, Charlotte’s Web products had only been available to Canadians that qualified for a special access medical exemption through Health Canada

Canada

Pathway's Medical Cannabis Management System (MCMS) will be implemented this November

M&A

The deal will help Flora establish a foothold in the German medical cannabis market